Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Rare Diseases

Carcinoma

Breast Neoplasms

Carcinoma, Ductal

Disease Progression

Carcinoma, Ductal, Breast

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Dilated Cardiomyopathy 1A

Nagwa Ahmed, Lecturer

Ahmed Rhoshdi, assistent prof

Background and Aim: Breast carcinoma is the most common type of cancer and the most common cause of cancer-related mortality among women worldwide. Cancer stem cells (CSCs) are thought to be responsible for tumor initiation, progression, dissemination and resistance to chemotherapy and radiotherapy. CD133 is a trans-membrane glycoprotein which is considered as a putative CSCs marker. It has been extensively used as a stem cell marker for normal and cancerous tissues. Emerging evidence suggests that CD133 may be a critical factor in tumor development, progression and metastasis. The aim of this study was to evaluate expression status of CD133 in invasive ductal carcinoma (IDC) of the breast and its role during breast cancer progression and to correlate its expression with some known clinicopathological parameters.

Introduction:

Breast carcinoma is the most frequent malignant tumor in women worldwide comprising 30% on average of all cancers and the most likely cause of cancer-related deaths in women worldwide. In Egypt, according to the official statistics of the National Cancer Institute, Cairo University, breast carcinoma is the most prevalent cancer among women representing 35.1% of total cancer cases.

Breast carcinoma is currently regarded as a heterogeneous group of tumors with diverse morphology, behavior, outcome and response to therapy. In spite of advances in diagnosis and treatment of breast carcinoma, the clinical outcome remains unsatisfactory due to recurrence, metastasis or chemotherapy-resistance.

Cancer stem cells (CSCs) are recognized as a subpopulation of cancer cells that show the characteristics of normal stem cells. They are believed to possess the capacity to self-renewal and are responsible for tumor formation and progression. CSCs also promote tumor cell heterogeneity and metastasis. In addition, CSCs are thought to be more resistant to chemotherapy and radiotherapy. Given the significance of CSCs in tumor development, the identification and characterization of CSCs could lead to the development of directed therapies against these aggressive cells, hence more effective treatments for cancer.

Over recent years, CSCs have been described in different types of cancers including breast cancer. In the mammary gland, the microenvironment provides clues to control the behavior of epithelial stem and progenitor cells. Breast cancer stem cells (BCSCs) subpopulation was shown to express higher level of pro-invasive genes and had highly invasive properties.

With evidence forthcoming regarding the effects of the stroma and the microenvironment in breast tumor progression, several genes have also been reported to be associated with BCSCs. The phenomenon of epithelial-mesenchymal transition (EMT) is important discovery during progression of breast carcinoma and explanation for their ability to invade and to colonize other parts of the body. With all these knowledge, targeting BCSCs for breast carcinoma treatment was demanded.

CD133, also known as prominin-1, is a member of pentaspan trans-membrane glycoproteins, frequently expressed on multipotent progenitor cells, including immature hematopoietic stem and progenitor cells. CD133 is a putative CSCs marker; it has been extensively used as a stem cell marker for normal and cancerous tissues. CD133 expressing cells possessing stem cell-like characteristics including self-renewal, high proliferation and drug resistance substantiating a tumorigenic role of CD133-expressing cells. It also plays a role in cell differentiation, proliferation and apoptosis.

Emerging evidences suggest that CD133 may be a critical factor in tumor development, progression and metastasis. CD133-positive CSC showed increased expression levels of CXCR4 which is a critical protein for the adhesion and/or migration of tumor cells, indicating an important role of CD133 in tumor cells migration and tumor invasion. CD133 is used as a diagnostic and prognostic marker which is overexpressed in various neoplasms. In breast cancer, its overexpression confers a poor prognosis. Increasing clinical evidence has confirmed that it is involved in breast cancer progression. CD133 is a promising marker for the identification of CSC in breast cancer subtypes including aggressive HER2+ and triple-negative classes.

Aim of This Work:

The aim of this study is to

1. Detect the immunohistochemical expression of CD133 in mammary invasive ductal carcinoma (IDC) and to correlate its expression with some known clinicopathological parameters.
2. Correlate the IHC expression of CD133 with some known clinicopathological parameters in mammary IDC.

CD133 Expression in Mammary Invasive Ductal Carcinoma

Significance of CD133 Expression in Invasive Ductal Carcinoma of the Breast

Sohag University

Lecturer at Pathology Department, Faculty of Medicine, Sohag University

Accuboost APBI

Jaroslaw Hepel, M.D.

To evaluate safety of 5 fraction accelerated partial brest irradiation in more convenient 5 fraction schedule.

The purpose of this study is to evaluate the rate of early and intermediate toxicity related to accelerated partial breast irradiation (APBI) delivered in a more convenient 5 fraction schedule using non-invasive image-guided breast brachytherapy (NIBB) (AccuBoost System) in women with resected, early stage breast cancer.

Non-invasive image-guided breast brachytherapy (NIBB), using advanced image-guided radiation technology, has the potential to eliminate the disadvantages of the conventional APBI techniques. NIBB facilitates non-invasive partial breast irradiation without the use of catheters or implants. Yet by using breast immobilization and precise image-guidance, it reduces non-target breast tissue within the irradiated field compared with other non-invasive APBI techniques such as 3D-CRT. This has made NIBB an attractive approach to deliver APBI.

We hypothesize that NIBB delivered in 5 treatments will be a more convenient, safe and effective modality to deliver partial breast irradiation.

Anticipated advantages of NIBB protocol treatment include:

* Convenient treatment schedule
* Short course can allow for increased patient access to treatment
* Non-invasive approach
* Increased accuracy with precise targeting of lumpectomy cavity using advanced imaging
* Reduced irradiation of non-target breast tissue
* Reduced skin toxicity
* No heart or lung radiation exposure
* Reduced late skin or breast toxicity
* High rate of good or excellent cosmetic outcome
* High rate of ipsilateral breast tumor control comparable to other APBI techniques

BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)

BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)

Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.

Watson cancer center

Cancer Treatment Centers of America

University of California, San Diego

Brown University

28Gy delivered in 5 daily fractions

Accuboost APBI: 28Gy delivered in 5 daily fractions

Age, Categorical

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Jaroslaw Hepel, MD

Number of Patients With Any Toxicity Related to the Radiation Treatment

Number of Participants With Ipsilateral Breast Local Recurrence

Overall Study

Dune Device

Dan Hershko, Dr.

Rona Spector, Dr.

Eran Sharon

Zvi Kaufman, Dr.

Tal Kopelman, Dr.

Yuri Berlin, Dr.

Moshe Papa, Prof.

Tanir Allweis, Dr.

Shlomo Schneebaum, Prof.

Moshe Carmon, Dr.

Amram Adari, Dr.

Moshe Zilberman, Dr.

This protocol was designed for testing the intraoperative use of the Dune device. This multicenter study will take place in Israel at 12 sites.

Use of the device will take place during a partial mastectomy procedure (lumpectomy).The patient will be randomized to enter the device or control arm.

Intraoperative Use of the BP Device for Detecting Positive Margins During Lumpectomy Procedure

MAST Study Protocol

Dune Medical Devices

Orit Yarden

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CD133 Expression in Mammary Invasive Ductal Carcinoma	NCT04873154	Breast Cancer		-	Sohag University
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)	NCT01961531	Breast Cancer	Accuboost APBI	50 Years -	Brown University
Intraoperative Use of the BP Device for Detecting Positive Margins During Lumpectomy Procedure	NCT00380952	Breast Cancer	Dune Device	18 Years -	Dune Medical Devices

Spots Global Cancer Trial Database for idc

Every month we try and update this database with for idc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for idc

Every month we try and update this database with for idc cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for idc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.